Edition:
United States

BioTime Inc (BTX.A)

BTX.A on American Stock Exchange

2.50USD
17 Nov 2017
Change (% chg)

$0.02 (+0.81%)
Prev Close
$2.48
Open
$2.46
Day's High
$2.58
Day's Low
$2.46
Volume
54,726
Avg. Vol
63,330
52-wk High
$3.96
52-wk Low
$2.19

Chart for

About

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem... (more)

Overall

Beta: 2.00
Market Cap(Mil.): $317.16
Shares Outstanding(Mil.): 126.87
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

BRIEF-BioTime presents updated Opregen phase I/IIa trial data at AAO

* There were no treatment-related serious adverse events after 15 months in trial​

Nov 15 2017

BRIEF-BioTime reports third quarter results

* BioTime reports third quarter results and recent corporate accomplishments

Nov 09 2017

BRIEF-BioTime Inc announces closing of public offering

* BioTime Inc announces closing of public offering and underwriters’ full exercise of over-allotment option Source text for Eikon: Further company coverage:

Oct 17 2017

BRIEF-Biotime announces pricing of $25 mln public offering of common stock

* Biotime, Inc. Announces pricing of $25.0 million public offering of common stock

Oct 13 2017

BRIEF-Biotime Inc announces proposed public offering of common stock

* Biotime Inc announces proposed public offering of common stock

Oct 12 2017

BRIEF-Biotime announces first patient in U.S. clinical trial treated for facial volume deficit

* Biotime announces first patient in U.S. Clinical trial treated for facial volume deficit

Oct 11 2017

BRIEF-BioTime and Processa announce their intention to enter into a HyStem® sublicense for drug delivery

* BioTime and Processa announce their intention to enter into a HyStem® sublicense for drug delivery

Oct 11 2017

BRIEF-BioTime announces positive data from Renevia pivotal trial

* BioTime announces positive secondary and additional positive long-term data from the Renevia® pivotal trial

Sep 26 2017

BRIEF-BioTime board approves distribution of Agex Therapeutics shares

* BioTime board of directors approves distribution of Agex Therapeutics shares to BioTime shareholders

Sep 25 2017

BRIEF-BioTime ‍announced conclusion of challenge to two key patents before European patent office opposition division​

* BioTime Inc - ‍Announced conclusion of challenge to two key patents before European patent office opposition division​ Source text for Eikon: Further company coverage:

Sep 14 2017

Competitors

  Price Chg
Sanofi SA (SASY.PA) €75.76 +0.33
Baxter International Inc (BAX.N) $63.88 -1.11
Hospira, Inc. (HSP.N) -- --

Earnings vs. Estimates